PentaBind

What it does

PentaBind pioneers a novel drug modality: ‘drug-like’ aptamers. Combining AI, proprietary wet-lab processes, molecular modelling, and the largest aptamer dataset, its platform optimises stability, folding, affinity, and specificity to drive an in-house pipeline of aptamer drugs. Their revenue-generating subsidiary accelerates AI development through aptamer design services. PentaBind was shortlisted by Cancer Research UK as New Startup of the Year.